Business Wire

Alsym Energy Emerges From Stealth To Provide Low-Cost, High-Performance Rechargeable Batteries

Share

Alsym™ Energy, a developer of next-generation rechargeable batteries, today announced that it is emerging from stealth to offer energy storage solutions for electric vehicles (EVs), stationary storage, and marine applications. Alsym’s battery technology promises to provide the performance of lithium-ion batteries at a fraction of the cost and without the inherent risk of fire. The company’s batteries are also less sensitive to raw material shortages and price volatility due to their use of low-cost materials with robust supply chains.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220615005167/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Alsym Energy works on its low-cost, high-performance rechargeable battery at R&D facility in Massachusetts. (Photo: Business Wire)

To accelerate the development of these affordable battery systems, Alsym is partnering with a leading India-based automaker in a joint effort to develop Alsym’s batteries for EVs. Conditional on key performance levels being met, the automaker will contract with Alsym to supply a minimum of 3 gigawatt hours (GWh) per year of battery systems for use in its products. Alsym is also in talks with companies in the marine shipping and electric two-wheeler markets to develop similar partnerships.

“Lithium is inherently flammable, and there are numerous risks that accompany all lithium-based battery technologies,” said Mukesh Chatter, CEO and Co-Founder of Alsym Energy. “Alsym Energy is on a mission to provide the world with cost-effective energy storage solutions using advanced, inherently non-flammable battery materials beyond lithium, made from non-toxic, readily available resources to power the growing mobility and stationary storage industries. We’re excited to work with industry partners to produce the next generation of batteries and to validate the innovations that will enable widespread access to clean electricity on a global scale.”

Alsym’s team of scientists and product developers is working to deliver and scale clean, energy-dense batteries that will be available at prices that are affordable to nearly anyone around the world. Founded in 2015, Alsym has raised $32 million to date from investors including Helios Climate Ventures.

“We’re seeing global competition to bring new batteries to market. Most companies are focused primarily on performance and put little thought into also making their batteries safer and more cost-effective—especially for the developing world where consumers are more price-sensitive,” said Nitin Nohria, Ph.D., Chairman of Alsym Energy’s Board of Business Advisors and former Dean of the Harvard Business School. “The team at Alsym Energy is working to ensure that their batteries not only meet performance expectations at reduced cost, but also avoid most of the supply chain challenges associated with lithium-based technologies. Not only are Alsym batteries sustainable, but the company’s business model is sustainable as well.”

The company estimates that Alsym batteries will cost less than half of current lithium-based batteries, enabling automakers to offer EVs at prices lower than comparable models with internal combustion engines. Using non-flammable, non-toxic materials removes many end-of-life concerns often associated with batteries, and Alsym batteries are much easier to recycle, helping ease the burden on waste processors, landfills, and others tasked with managing battery waste.

Alsym is currently in the process of developing a 500-kWh prototype manufacturing facility in Massachusetts. Because the materials used are non-flammable and non-toxic, Alsym batteries can be easily built in nearly any industrial site. They can also be made in existing lithium-ion battery factories with little to no retrofitting required, at lower operating cost and without the need for expensive dry rooms, fire locks, and solvent recovery systems.

About Alsym Energy
Alsym™ Energy is a leading developer of advanced low-cost, high-performance rechargeable batteries made from readily available materials that are inherently non-flammable and non-toxic, providing an economically viable alternative to lithium-based technologies. The company is focused on commercial development and mass production of batteries for use in applications including passenger electric vehicles and two-wheelers, marine shipping, and stationary energy storage to enable a zero-carbon future. To learn more, please visit www.alsym.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media
Cassandra Sweet
Antenna Group for Alsym Energy
alsym@antennagroup.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Teva Announces Promising Interim Results From Its Study PEARL, About the Impact of AJOVY ® (fremanezumab)24.6.2022 18:54:00 CEST | Press release

Teva Pharmaceuticals Europe B.V. today announces promising interim results from its Pan-European Real World study (PEARL), presented for the first time at the European Academy of Neurology (EAN) Congress in Vienna, Austria. The two-year Pan-European Real World (PEARL) prospective, observational study of AJOVY® (fremanezumab), looks at its effectiveness in patients with chronic migraine or episodic migraine, and is an ongoing study sponsored by Teva Pharmaceuticals Europe BV.1 These findings further offer insight into the treatment of migraine in real-world clinical practice. The interim findings were presented by Faisal Mohammad Amin, Associate Professor of Neurology at the University of Copenhagen, Denmark. Out of the total planned 1100 patients in PEARL, 389 patients are included in the interim analysis presented. These findings show that 54.7% of patients in the study had their monthly-migraine-days reduced by 50% or more, over the six-month period from the start of treatment. Addit

Brigade-M3 European Acquisition Corp. 2021 Annual Report24.6.2022 16:59:00 CEST | Press release

Brigade-M3 European Acquisition Corp. (the “Company”), a special purpose acquisition company that was incorporated on 21 April 2021 under the laws of the Cayman Islands as an exempted company with limited liability and is listed on Euronext Amsterdam, today published its annual report for the period 21 April 2021 to 31 December 2021. The full report can be downloaded from the Company’s website via the following link: https://www.brigadem3eac.com/documents IMPORTANT INFORMATION This press release contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. DISCLAIMER This announcement is not for distribution or release, directly or indirectly, and should not be distributed in or sent into, the United States, Australia, Canada, Japan, the Cayman Islands or South Africa or any other jurisdiction in which such distribution or release would be unlawful or would require registration or other measures. This announcement does n

PUMA Kicks Off Its Largest Web3 Collaboration To Date, with 10KTF Shop24.6.2022 16:41:00 CEST | Press release

PUMA has entered New Tokyo, the virtual city 10KTF calls home. The shop is known for its streetwear offerings and is owned by Wagmi-san, a digital artisan whose collections and NFT community recently welcomed the global sports brand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220624005314/en/ PUMA Kicks Off Its Largest Web3 Collaboration To Date, with 10KTF Shop PUMA has entered New Tokyo, the virtual city 10KTF calls home. The shop is known for its streetwear offerings and is owned by Wagmi-san, a digital artisan whose collections and NFT community recently welcomed the global sports brand. (Photo: Business Wire) News of the partnership was shared at an event hosted by 10KTF last night in New York. Their event was one of many hosted during the week of NFT.NYC, a conference attended by crypto industry professionals, traders, and other web3 enthusiasts. The official announcement confirms weeks of speculation after PUMA tw

Suzano outlines ESG milestone achievements and commitments at second annual ESG call24.6.2022 16:14:00 CEST | Press release

Suzano, the world’s largest hardwood pulp producer, today held its second annual ESG Call centered around its ambition to be a ‘regenerative company for a regenerative society’. Today’s ESG Call spotlighted measurable progress and ambitions across three core areas of action: climate change, biodiversity and social development. On Climate Change, the ACT initiative of the French Government and CDP scored Suzano ahead of its pulp and paper industry peers in virtually every metric. In 2021, Suzano brought forward its target for removing 40 million tons of carbon dioxide from the atmosphere from 2030 to 2025 which is being achieved through improvements to its industrial processes, such as systematically replacing the use of fossil fuels at its industrial plants with biomass, and through conversion of degraded land. As part of the company’s social commitments, Suzano launched a target in 2020 to lift 200,000 people out of poverty. This is more than pertinent, given that in Brazil, 10% of th

Kyowa Kirin Receives Positive CHMP Opinion for Use of CRYSVITA ® ▼ (burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)24.6.2022 15:38:00 CEST | Press release

Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended that CRYSVITA® (burosumab) be approved for the treatment of FGF23-related hypophosphataemia in Tumour-Induced Osteomalacia (TIO) associated with phosphaturic mesenchymal tumours (PMTs) that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.1 CRYSVITA is also already licensed for use in the rare disease X-Linked Hypophosphataemia (XLH), for children and adolescents between 1 and 17 years of age with radiographic evidence of bone disease, and in adults.2 Also known as oncogenic osteomalacia, TIO is an acquired disorder caused by typically small, slow-growing, benign PMTs.3,4 It is a rare condition with less than 1000 cases reported in the medical literature,4 which mainly affects adults and with a mean onset age of 40 – 45 years.3,5 TIO is associated with p

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom